Year None202220212020201920182017201620152014201320122011 May 09, 2022 Ultragenyx Announces Upcoming Data Presentations at American Society of Gene & Cell Therapy (ASGCT) 2022 Annual Meeting Read More May 05, 2022 Ultragenyx Reports First Quarter 2022 Financial Results and Corporate Update Read More May 03, 2022 Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Read More May 03, 2022 Ultragenyx to Participate at BofA Securities 2022 Healthcare Conference Read More Apr 27, 2022 Ultragenyx to Host Conference Call for First Quarter 2022 Financial Results and Corporate Update Read More Apr 25, 2022 Ultragenyx Issues Inaugural Environmental, Social and Governance (ESG) Report Read More Apr 22, 2022 Ultragenyx Appoints Amrit Ray, M.D., M.B.A. to Board of Directors Read More Apr 20, 2022 Ultragenyx Announces First Patient Dosed in Pivotal Phase 2/3 Clinical Study of Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta Read More Mar 02, 2022 Ultragenyx to Participate in the Cowen Health Care Conference Read More Feb 10, 2022 Ultragenyx Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Update Read More Pagination First page « first Previous page ‹ previous Page 1 Page 2 Current page 3 Page 4 Next page next › Last page last » Displaying 21 - 30 of 37
May 09, 2022 Ultragenyx Announces Upcoming Data Presentations at American Society of Gene & Cell Therapy (ASGCT) 2022 Annual Meeting Read More
Apr 27, 2022 Ultragenyx to Host Conference Call for First Quarter 2022 Financial Results and Corporate Update Read More
Apr 20, 2022 Ultragenyx Announces First Patient Dosed in Pivotal Phase 2/3 Clinical Study of Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta Read More
Feb 10, 2022 Ultragenyx Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Update Read More
